[Advances in combination therapy of ombitasvir and dasabuvir for chronic hepatitis C virus genotype 1 infection].
Zhonghua Gan Zang Bing Za Zhi
; 26(9): 710-713, 2018 Sep 20.
Article
em Zh
| MEDLINE
| ID: mdl-30481875
ABSTRACT
Since 2014, the United States and Europe has approved all oral, interferon free- regimens that combine with direct-acting antiviral agents. Hence, the sustained virological response rate of patients with chronic HCV genotype 1 infection has improved over 90%, and the treatment modalities has introduced a new era. These drugs, ombitasvir and dasabuvir, received customary authorization of Food and Drug Administration in 2015 and are the first combined direct-acting antiviral agents for treating HCV genotype 1 infection. It has superior application prospects in China because of its high-sustained virological response rate and safety profile. This article reviews the pharmacokinetics, drug interactions, efficacy and safety of this therapeutic regimen.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Sulfonamidas
/
Uracila
/
Carbamatos
/
Hepacivirus
/
Hepatite C Crônica
/
Quimioterapia Combinada
/
Anilidas
Limite:
Humans
País/Região como assunto:
America do norte
Idioma:
Zh
Revista:
Zhonghua Gan Zang Bing Za Zhi
Assunto da revista:
GASTROENTEROLOGIA
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
China